10-Q 1 form10q.htm FORM10-Q Cybrdi, Inc.: Form 10-Q - Filed by newsfilecorp.com

United States
Securities and Exchange Commission

Washington, D.C. 20549

FORM 10-Q

[ X ]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

OR

[    ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No: 09081

CYBRDI, INC.
(Exact name of registrant as specified in its charter)

CALIFORNIA
(State or other jurisdiction of incorporation or organization)

95-2461404
(I.R.S. Employer ID No)

No 29 Chang'An South Road Xi'an Shaanxi P.R. China 71006 1
(Address of principal executive office) (Zip Code)
Registrant's telephone number: (011) 86-29-8237-3068

N/A
Former name, former address and former fiscal year,

(if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [ X ]   No [   ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [   ]   No [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [   ] Accelerated filer [   ] Non-accelerated filer [   ] Smaller reporting company [ X ]
    (Do not check if a smaller reporting  
    company)  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [   ]   No [ X ]

The number of shares of common stock, no par value per share, outstanding as of August 19, 2011 was 65,756,567.

1



CYBRDI, INC.
FORM 10-Q
QUARTERLY PERIOD ENDED JUNE 30, 2011
INDEX

TABLE OF CONTENTS

           Page
  PART I – FINANCIAL INFORMATION  
Item 1: Financial Statements 3
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
Item 3: Quantitative and Qualitative Disclosures About Market Risk 18
Item 4T: Controls and Procedures 19
  PART II – OTHER INFORMATION  
Item 1: Legal Proceedings 19
Item 1A: Risk Factors 19
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 19
Item 3: Defaults Upon Senior Securities 19
Item 4: Submission of Matters to a Vote of Security Holders 19
Item 5: Other Information 19
Item 6: Exhibits 20

2


PART I. FINANCIAL INFORMATION

Item 1 Financial Statements

 

 

3



CYBRDI, INC. AND SUBSIDIARIES   
CONSOLIDATED BALANCE SHEETS   
    June 30, 2011     December 31, 2010  
ASSETS   (Unaudited)     (Audited)  
CURRENT ASSETS            
     Cash and equivalents $  524,208   $  585,020  
     Inventories   1,129,380     1,090,154  
     Due from related companies   247,544     204,474  
     Loan to unaffiliated company,net   23,207     90,877  
     Other receivables and prepaid expenses   92,779     96,949  
     Advance to suppliers   9,654     -  
TOTAL CURRENT ASSETS   2,026,772     2,067,474  
PROPERTY, PLANT AND EQUIPMENT, NET   1,311,659     1,314,979  
CONSTRUCTION IN PROGRESS   6,105,086     6,557,391  
INTANGIBLE ASSETS, NET   819,968     226,219  
TOTAL ASSETS $  10,263,485   $  10,166,063  
LIABILITIES AND EQUITY            
CURRENT LIABILITIES            
     Short-term loan $  1,624,507   $  1,590,355  
     Accounts payable   4,708     4,609  
     Accrued expenses   560,593     505,054  
     Deferred revenue   26,641     21,749  
     Customers deposits   154,671     150,522  
     Due to related parties   2,268,323     2,023,674  
     Deferred tax liabilities   10,022     9,812  
     Other payables   50,470     77,209  
TOTAL CURRENT LIABILITIES   4,699,935     4,382,984  
CONSTRUCTION PAYABLE   825,787     808,427  
TOTAL LIABILITIES   5,525,722     5,191,411  
EQUITY            

  Preferred Stock, $1.00 per value, 500,000 shares authorized, no shares issued and outstanding

  -     -  

  Common Stock, no par value, 150,000,000 shares authorized, 65,756,567 shares issued and outstanding

  3,877,864     3,877,864  
     Reserve funds   336,885     336,885  
     Accumulated deficit   (2,121,407 )   (1,847,882 )
     Accumulated other comprehensive income   1,377,543     1,287,737  
TOTAL STOCKHOLDERS’ EQUITY   3,470,885     3,654,604  
NONCONTROLLING INTEREST   1,266,878     1,320,048  
TOTAL EQUITY   4,737,763     4,974,652  
TOTAL LIABILITIES AND EQUITY $  10,263,485   $  10,166,063  

See notes to consolidated financial statements.

4



 CYBRDI, INC. AND SUBSIDIARIES    
CONSOLIDATED STATEMENTS OF OPERATIONS    
 (UNAUDITED)     
   
    Three Months Ended     Three Months Ended     Six Months Ended     Six Months Ended  
    June 30, 2011     June 30, 2010     June 30, 2011     June 30, 2010  
Revenue                        
     Housing $  -   $  41,835   $  -   $  136,450  
     Commercial rental   -     -     -     -  
     Tissue array products   123,419     105,107     237,230     202,937  
          Total revenue   123,419     146,942     237,230     339,386  
Cost of Sales                        
     Housing   -     48,923     -     133,792  
     Commercial rental   17,125     -     31,752     -  
     Tissue array products   102,176     101,493     189,324     165,952  
          Total cost of sales   119,301     150,416     221,076     299,744  
Gross Profit   4,118     (3,474 )   16,154     39,642  
Operating Expenses:                        
     Salaries and wages   41,093     45,357     81,576     389,036  
     Depreciation and amortization   36,721     35,376     72,993     70,733  
     Bad debt expense   23,226     41,943     68,830     41,943  
     Professional fees   10,782     8,659     57,108     32,886  
     Selling and distribution expenses   3,786     11,291     10,211     17,966  
     Other general and administrative expenses   25,407     62,386     51,762     68,342  
     Research and development expenses   -     2,754     -     10,157  
Total Operating Expenses   141,015     207,766     342,480     631,063  
Loss from Operations   (136,897 )   (211,240 )   (326,326 )   (591,421 )
Other Income (Expense)                        
     Interest income (expense)   (1,085 )   426     (598 )   1,274  
     Other income (expense), net   (14 )   429     229     27,518  
Total Other Income (Expense), Net   (1,099 )   855     (369 )   28,792  
Loss before Income Taxes   (137,996 )   (210,386 )   (326,695 )   (562,630 )
Income Tax Benefit (Expense)   -     -     -     -  
Net loss   (137,996 )   (210,386 )   (326,695 )   (562,630 )
Net loss attributable to the noncontrolling interest   (28,160 )   (37,036 )   (53,169 )   (37,140 )
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES $  (109,836 ) $  (173,350 ) $  (273,526 ) $  (525,490 )
Net Loss Per Common Share                        
     Basic and Diluted $  (0.00 ) $  (0.00 ) $  (0.00 ) $  (0.01 )
Weighted Average Number of Shares Outstanding                        
     Basic and Diluted   65,756,567     64,566,567     65,756,567     64,566,567  

See notes to consolidated financial statements.

5



CYBRDI INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
    Six Months Ended     Six Months Ended  
    June 30, 2011     June 30, 2010  
CASH FLOWS FROM OPERATING ACTIVITIES            
     Net Loss $  (273,526 ) $  (525,490 )
    Adjustments to Reconcile Net Loss to Net Cash Provided by Operating Activities:        
               Depreciation and amortization   135,345     95,264  
               Bad debt expense   68,830     41,943  
               Minority interest   (53,169 )   (37,140 )
               Issuance of common shares for compensation   -     306,000  
               Gain on sale of other assets   -     (28,250 )
     Changes in Operating Assets and Liabilities:            
               Accounts receivable   -     8,516  
               Inventories   (15,636 )   152,245  
               Other receivable and prepaid expenses   (3,365 )   (39,108 )
               Accounts payable and other current liabilities   81,043     (106,437 )
               Deferred revenue   -     5,675  
               Customer deposits   906     (5,789 )
     Net Cash Used in Operating Activities   (59,571 )   (132,571 )
CASH FLOWS FROM INVESTING ACTIVITIES            
               Net proceeds from disposal of other assets   -     67,325  
               Advance for loan to affiliated companies   (38,480 )   (117 )
               Purchase of property, plant, and equipment   (46,523 )   (32,895 )
               Payments for construction in progress   (87,100 )   (331,058 )
     Net Cash Used in Investing Activities   (172,104 )   (296,745 )
CASH FLOWS FROM FINANCING ACTIVITIES            
               Proceeds from loans from related companies   36,710     118,136  
               Proceeds from shareholders/officers   122,469     -  
     Net Cash Provided by Financing Activities   159,178     118,136  
NET DECREASE IN CASH & CASH EQUIVALENTS   (72,497 )   (311,179 )
EFFECT OF EXCHANGE RATE CHANGE ON CASH & CASH EQUIVALEN   11,685     (1,548 )
CASH & CASH EQUIVALENTS, BEGINNING BALANCE   585,020     861,457  
CASH & CASH EQUIVALENTS, ENDING BALANCE $  524,208   $  548,730  
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION            
               Interest paid $  86,084   $  64,893  
               Income taxes paid $  -   $  -  
NONCASH INVESTING TRANSACTIONS            
               Construction-in-progress incurred by accrued construction payable $  17,360   $  70,242  
               Debt-Equity Conversion $  -   $  -  

See notes to consolidated financial statements.

6


CYBRDI, INC. AND SUBSIDIDARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. Interim Financial Statements

The unaudited consolidated financial statements of Cybrdi Inc. and subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the requirements for reporting on Form 10-Q. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. However, the information included in these interim financial statements reflects all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for the fair presentation of the consolidated financial position and the consolidated results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full year. The consolidated balance sheet information as of December 31, 2010 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K. These interim financial statements should be read in conjunction with that report. Certain comparative amounts have been reclassified to conform to the current period's presentation.

The consolidated financial statements include the accounts of Cybrdi, Inc. and its wholly-owned subsidiaries and joint ventures. All material intercompany balances and transactions have been eliminated.

2. Description of Business

Cybrdi, Inc. (f/k/a Certron Corporation) (the “Company” or “Cybrdi”) was incorporated on August 1, 1966, under the laws of the State of California. Until around June 2004, the Company’s business consisted of the distribution of magnetic media products, primarily blank audio and video cassettes. Due to continuing intense price competition and technological changes in the marketplace for its products, the Company lost its remaining significant customers and disposed of or wrote off its remaining inventory. As a result of these occurrences, the Company concluded that its audio and videotape businesses were no longer viable and some of its product lines were obsolete.

On February 10, 2005, the Company, through a wholly-owned subsidiary, acquired all the ownership interest in Cybrdi, Inc., a privately held company incorporated in the State of Maryland ("Cybrdi Maryland"). As a result of the ownership interests of the former shareholders of Cybrdi Maryland, for financial statement reporting purposes, the transaction was treated as a reverse acquisition, with Cybrdi Maryland deemed the accounting acquirer and Certron Corporation deemed the accounting acquiree. Historical information of the surviving company is that of Cybrdi Maryland.

Cybrdi Maryland was established in 2001 to acquire an interest in biogenetic products commercialization and related services entities in Asia. On March 5, 2003, Cybrdi Maryland acquired an 80% interest in Shaanxi Chao Ying Biotechnology Co., Ltd. (“Chaoying Biotech”), a sino-foreign equity joint venture established in July 2000 in the People's Republic of China (“PRC”), through the exchange of 99% of the Company’s shares to the existing shareholders of Chaoying Biotech. For financial statement reporting purposes, the merger was treated as a reverse acquisition, with Chaoying Biotech deemed the accounting acquirer and Cybrdi Maryland deemed the accounting acquiree.

Chaoying Biotech is a sino-foreign equity joint venture between Shaanxi Chaoying Beauty & Cosmetics Group Co., Ltd. (the “Chinese Partner”, a PRC corporation) and Immuno-Onco Genomics Inc. (the “Foreign Partner”, a USA corporation). The joint venture agreement has a 15 year operating period starting from its formation in July 2000 and it may be extended upon mutual consent. The principal activities of Chaoying Biotech are research, manufacture and sale of various high-quality tissue arrays and the related services in the PRC.

Most of the Company’s activities are conducted through Chaoying Biotech. Chaoying Biotech, with its principal operations located in China, aims to take advantage of China's abundant scientific talent, low wage rates, less stringent biogenetic regulation, and the huge genetic population as it introduces its growing list of tissue micro array products.

7


On February 10, 2005, the Company completed the merger with Cybrdi Maryland and changed its name to Cybrdi, Inc.

On July 26 , 2007, Chaoying Biotech entered into an acquisition agreement with its Chinese partner, which is a principal shareholder of the company, Mr. Bai, the Company’s chief executive officer and a director is also a principal of its Chinese partner On July 28,2007, Chaoying Biotech invested RMB15 millions (equivalent to US$1,983,078) to acquire an 83.33% equity ownership of Shandong Chaoying Culture and Entertainment Co., Ltd. (“SD Chaoying”) from its Chinese partner, SD Chaoying is a corporation organized in Shandong Province P.R.China. On September 5, 2007, Shandong Commercial government had approved this acquisition and the ownership title of SD Chaoying had been transferred to Chaoying Biotech from its Chinese partner. The future business of SD Chaoying will primarily focus on culture and entertainment, including spa activities, cosmetic and personal care, body building, gambling, catering, and lodging, etc. SD Chaoying will have a specific emphasis on casino gambling, which has been approved by Shandong Administration for Civil Affairs. As of December 31, 2009, SD Chaoying had substantially completed the construction of two residential buildings and had recognized revenue from sales of housing for 2009. The main structure of the commercial entertainment center has also been completed, except for the exterior, rooftop, the surrounding supporting projects and the community landscaping, which are expected to be completed in 2011 prior to the commencement of operations by merchant tenants if we can obtain an estimated $2.8 million to complete construction.

On March 10, 2007 the Company entered into a Sales Agency Agreement with BioMax, Ltd., a reseller located in the United States.

Chaoying Biotech invested $154,732 (equivalent to RMB 1 million) to restore a previously established Institute of Shaanxi Chaoying Clinical Pathology (“IOSCCP”) on April 29, 2011 and held 100% of the equity interest. Shaanxi Chaoying Clinical Pathology Institute is a privately held entity established on July 31, 2003, whose main business includes pathology research and consulting, consulting and diagnostic clinical pathology and pathology-related research and development of new technologies, and basic training in pathology. Its sole shareholder has been Chaoying Biotech. However, Chaoying Biotech withdrew the original investment in IOSCCP in September 2007 as we believed that both internal and external conditions of IOSCCP were not mature at that time. In light of foreseeable benefits and new business opportunities from operating this entity, we resumed its business and re-invested $154,732 (equivalent to RMB 1 million)  in it in April 2011.

3. Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has not demonstrated the ability to generate sufficient cash flows from operations to satisfy its liabilities and sustain operations. The Company had an accumulated deficit of $2,121,407 and $1,847,882 as of June 30, 2011 and December 31, 2010, including net losses of $273,526 and $525,490 for the six months ended June 30, 2011 and 2010, respectively. In addition, current liabilities exceeded current assets by $2,673,163 and $2,315,510 at June 30, 2011 and December 31, 2010, respectively. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

The Company finances its operations primarily through short-term bank borrowings and advances from related parties and/or officers/shareholders. In order to complete the construction of SD Chaoying cultural and entertainment center, approximately $2.8 million (equivalent to RMB 19 million) of capital is expected to be needed. The Company, taking into account the available banking facilities, internal financial resource, and supports from related companies, believes it has sufficient working capital to meet its present obligation for at least the next twelve months. Management is taking actions to address the company's financial condition and deteriorating liquidity position. The following sets forth management’s plans for dealing with the adverse effects of the conditions:

(a)     Sale of housing inventories: Proceeds to be received from the sale of the remaining housing of the two completed residential buildings are expected to amount to approximately $1.1 million.

(b)    Rental and management fee revenue from the cultural and entertainment center: Annual rental revenue is estimated to be approximately $650,000 per year. Management fee revenue will be charged to commercial tenants at 3% of annual gross revenue.

(c)    Additional advances from related companies and affiliates: Mr. Bai, our Chief Executive Officer, advanced $61,209 to the Company in 2011 to finance operations and the costs to maintain the Company’s public status in the U.S. In addition, Shaanxi Chaoying Beauty & Cosmetics Group, which is also an affiliate, is anticipated to provide up to $764,780 (equivalent to RMB 5 million) of capital to support operations. During 2011, Shaanxi Chaoying Beauty & Cosmetics Group advanced $36,710 to the Company to finance its operations.

The Company may require additional funds and may seek to raise such funds though public and private financings or from other sources. There is no assurance that management’s plans will be realized or the additional financing will be available at all or that, if available, such financing will be obtainable on terms favorable to the Company or that any additional financing will not be dilutive. The consolidated financial statements do not include any adjustments that might result from the outcome of those uncertainties.
 

8


4. Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

5. Revenue Recognition

Revenue represents the invoiced value of goods sold recognized upon the delivery of goods to customers and service income is recognized when services are provided. Deferred revenue represents the undelivered portion of invoiced value of goods sold to customers. Sales transactions not meeting all the conditions of the full accrual method are accounted for using the deposit method of accounting. Under the deposit method, all costs are capitalized as incurred, and payments received from the buyer are recorded as customer deposits.

6. Reverse Merger

On February 10, 2005, (the "Closing Date") the Company closed on an Agreement and Plan of Merger (the "Agreement") among Certron Corporation (“Certron”), a California corporation, Certron Acquisition Corp., a Maryland corporation and a wholly-owned subsidiary of Certron ("Acquisition Sub"), and Cybrdi, Inc., a Maryland corporation (“Cybrdi – Maryland”) relating to the acquisition by Certron of all of the issued and outstanding capital stock of Cybrdi -Maryland in exchange for shares of common stock of Certron that will aggregate approximately 93.8% of the issued and outstanding common stock of Certron. Pursuant to the terms of the Agreement, at the Closing Date (a) Acquisition Sub has been merged with and into Cybrdi - Maryland, with Cybrdi - Maryland being the surviving corporation, (b) the common stock of Cybrdi-Maryland has been cancelled and converted into the right to receive shares of the common stock of Certron at an exchange ratio of 1.566641609 per share. This resulted in the issuance of 47,328,263 shares of the Certron’s common stock, and (c) each share of the common stock of Acquisition Sub has been converted in to and become one share of the common stock of Cybrdi-Maryland. The share exchange has been accounted for as a reverse merger under the purchase method of accounting. Accordingly, Cybrdi, Inc. will be treated as the continuing entity for accounting purposes and the historical financial statements presented will be those of Cybrdi, Inc.

In connection with the Agreement, on February 10, 2005, the Company amended its articles of incorporation to authorize the issuance of 150 million shares of common stock no par value and 500,000 shares of preferred stock, $1.00 par value per share, none of which are issued or outstanding.

Concurrent with the filing of the Articles of Merger, all of the Company then existing officers and directors tendered their resignation and Yanbiao Bai was appointed as its Chairman of the Board of Directors. Mr. Bai then nominated the balance of the Board of Directors.

7. Income Taxes

Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to the differences between the basis of assets and liabilities for financial and income tax reporting. The deferred tax assets and liabilities represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes also are recognized for operating losses that are available to offset future income taxes.

9


8. Recent Accounting Pronouncements

The Company has adopted all recently issued accounting pronouncements. The adoption of the accounting pronouncements, including those not yet effective, is not anticipated to have a material effect on the financial position or results of operations of the Company.

NOTE B – ASSETS

The June 30, 2011 balance sheet included total current assets of $2,026,772 and non-current assets of $8,236,713. Of these amounts, $524,208 in cash and equivalents is planned for funding current operations and for future business expansion.

Other current assets also included inventories, due from related companies, loan to unaffiliated company, and other receivables and prepaid expenses. Inventories are mainly finished goods. Other components of inventories include raw materials, work in process, packaging material and housing inventories. Inventories are stated at the lower of cost or market. Cost of raw materials is determined on the basis of first in first out method (“FIFO”). Finished goods are determined on the weighted average basis and are comprised of direct materials, direct labor, and an appropriate proportion of overhead.

The other primary assets included in current assets are loans to an unaffiliated company, QuanYe Security Co., Ltd (“QuanYe”), an unrelated PRC registered company located in Xian, PRC. QuanYe is engaged in the pawnshop business and its primary business is offering alternative financing sources to small, local companies. According to the loan agreement, QuanYe has received loans from Chaoying Biotech in a total amount of RMB 29.3 million (equivalent to $3,849,185) since January 2006. A remaining balance of RMB 7.3 million (equivalent to $1,069,989) was extended to and expired on March 24, 2008. As of June 30, 2011, the principal balance and interest receivable for this loan had been reduced to RMB 0.15 Million (equivalent to $23,207) and RMB 0, respectively, net of allowance of $69,622 and $177,177 for doubtful principal balance receivable and interest receivable after charging $68,830 of bad debt expense for the six-month period ended June 30, 2011. The interest rate for these loans initially was initially 8% per year, and subsequently reduced to 5% since October 9, 2006.

The Company’s management believes and views QuanYe as suitable alternative financial institution and it is an optimal way to use its cash on hand. The regular market interest rate in the PRC is proximately 0.72% per annum. The Company expects to obtain higher interest income for its unused fund through these types of loan arrangements. However, these advances are unsecured and have a default risk higher than that associated with a bank deposit.

Included in non-current assets are property, plant and equipment, construction-in-progress and intangible assets. Property, plant and equipment mainly consist of building, office equipments, motor vehicles, leasehold improvement, software-website, and machinery used for product manufacturing located in the People’s Republic of China (“PRC”). Depreciation on property, plant and equipment is computed using the straight-line method over the estimated useful life of the assets. The majority of the assets have estimated useful lives of 10 years. Building and office equipment have estimated useful lives of 20 and 5 years, respectively. The “construction in progress” in the amount of $6,105,086 mainly consisted of land under development and construction of the entertainment, culture, and casino facility in Shandong Province, which will be transferred to fixed assets in SD Chaoying when construction is completed. As of June 30, 2011, construction-in-progress of $3.65 million and land use rights of $3.09 million of SD Chaoying were collateralized under a short-term loan from Changle Rural Credit Union. For the $3.09 million land use rights, $2.45 million was classified under construction-in-progress for the commercial property and the remaining $0.64 million was classified under intangible assets subject to amortization. Intangible assets included a tissue chip patent at Chaoying Biotech and $0.64 million of land use rights being put in operation for the partial completed commercial property at SD Chaoying. Effective January 1, 2002, with the adoption of the accounting guidance for Goodwill and Other Intangible Assets, intangible assets with a definite life are amortized on a straight-line basis. The patent is being amortized over its estimated life of 10 years. The land use rights classified in intangible asset is being amortized over its estimated life of 36.9 years through the maturity of the land use rights for commercial use on November 6, 2047.

10


NOTE C - LIABILITIES

As of June 30, 2011, the balance sheet included total liabilities of $5,525,722, which consisted of current liabilities of $4,699,935 and construction payable of $825,787. Included in the current liabilities was a short-term loan of $1,469,791 (equivalent to RMB 9.5 million) from Changle Rural Credit Union, which is a bank located in Shandong Province of the PRC. This short-term loan had been secured by the Company’s land use right and construction-in-progress of SD Chaoying with a book value of $3.09 million (equivalent to RMB 20.03 million) and $3.65million (equivalent to RMB 23.59 million) as of June 30, 2011, respectively. For the $3.09 million land use rights, $2.45 million was classified under construction-in-progress for the commercial property and the remaining $0.64 million was classified under intangible assets subject to amortization. The original term of the loan was from August 25, 2009 to August 24, 2010 with an interest rate of 7.965% per annum. The Company renewed the loan with the bank for a new term from August 31, 2010 to August 25, 2011 (total of twelve months) with annual interest rate at 9.558% . Additionally, there is another short-term loan of $154,715 (equivalent to RMB 1.0 million) from Fengguo Liu, an unrelated party. Also included in the current liabilities was $2,268,323 of loans from related companies, including Xi’an Yanfeng Biotechnology Co., Ltd., Shaanxi Yanfeng Real Estate Co. Ltd, Shaanxi Chaoying Beauty & Cosmetics Group Co., Ltd and the stockholders who are also the Company’s officers. These entities were related to the Company through common ownership and principal officers. These loans are non-interest bearing and have no set repayment terms.

NOTE D – STOCKHOLDERS’ EQUITY

As a result of the reverse merger (see Note A item 6), the common stock of Cybrdi-Maryland has been cancelled and converted into shares of common stock of Certron at an exchange ratio of 1.566641609 per share. This resulted in the issuance of 47,328,263 shares of Certron’s common stock to the Cybrdi shareholders. As of June 30, 2011 and December 31, 2010, the Company had 65,756,567 shares issued and outstanding.

As of June 30, 2011, the balance sheet included total equity of $4,737,763, of which $1,266,878was for non-controlling interest, representing 20% minority interest in Chaoying Biotech and 16.67% minority interest in SD Chaoying.

On January 15, 2010, the Board of Directors adopted resolutions that authorized incentive compensation to key management of the Company for services it has provided to the Company. As set forth in the Board of Directors’ resolution dated January 15, 2010, the incentive compensation shall be paid by the issuance of 12,000,000 shares of common stock of the Company to Mr. Yanbiao Bai, Chief Executive Officer and President of the Company, and 3,300,000 shares of common stock of the Company to Ms. Xue Bu, Chief Financial and Operating Officer of the Company. Compensation cost of $306,000 was recorded during the first quarter of 2010 at $0.02 per share, the market price of the Company’s common stock on January 15, 2010, the grant date.

NOTE E – INCOME TAXES

Under the Enterprise Income Tax (“EIT”) of the PRC, prior to 2007, Chinese enterprises are generally subject to an income tax at an effective rate of 33% (30% statutory income taxes plus 3% local income taxes) on income reported in the statutory financial statements after appropriate tax adjustments, unless the enterprise is located in a specially designated region for which more favorable effective tax rates are applicable. Beginning on January 1, 2008, the new EIT law has replaced the existing laws for Domestic Enterprises (“DEs”) and Foreign Invested Enterprises (“FIEs”). The new standard EIT rate of 25% will replace the 33% rate previously applicable to both DES and FIEs. The two year tax exemption, six year 50% tax reduction and tax holiday for production-oriented FIEs will be eliminated. According to the Western Developing Plan implemented by the PRC Government, Chaoying Biotech is entitled to a 50% reduction in EIT of preferential policy, but not less than 15%. As a result, Chaoying Biotech’s effective EIT tax rate has been 15% since 2008.

The Company’s income tax expense includes U.S. and PRC income taxes. There were no U.S. current taxes for the three months ended June 30, 2011 according to net loss incurred in the U.S. entity, which will not be anticipated to have any tax benefit in the future since no revenue is expected to be generated in the U.S as a result of discontinuing the U.S. operating company in Maryland in October 2007. There were also no PRC current taxes for the three months ended June 30, 2011 due to net loss incurred.

11


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation

The following discussion and analysis should be read in conjunction with the company’s Financial Statements and Notes thereto appearing elsewhere in this Report on Form 10-Q as well as the company’s other SEC filings, including our annual report on Form 10-K for the year ended December 31, 2010.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this quarterly report on Form 10-Q contain or may contain forward-looking statements that are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause its actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond its control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this quarterly report in its entirety, including but not limited to its financial statements and the notes thereto. Except for its ongoing obligations to disclose material information under the Federal securities laws, the Company undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. For any forward-looking statements contained in any document, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. This report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe," "Cybrdi believes," "management believes" and similar language. The forward-looking statements are based on the current expectations of Cybrdi and are subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under "Description of Business" and "Management's Discussion and Analysis." The actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them.

PLAN OF OPERATIONS

The Company focuses on biogenetics commercialization and healthcare product applications. The Company’s primary business includes sales of tissue microarray products and services. Tissue chips, also called micro tissue arrays, provide high-throughput molecular profiling and parallel analysis of biological and molecular characteristics for hundreds of pathologically controlled tissue specimens. Tissue arrays can provide rapid and cost-effective localization and evaluation of proteins, RNA, or DNA molecules, which is particularly useful for functioning genomic studies. Cybrdi manufactures both human and animal tissue microarray for a wide variety of scientific uses, including drug discovery and development purposes.

The Company’s business strategy and focus in the near future include

  • Enhancing R&D in TMAs and technical service

  • Expanding its product portfolio and virtual tissue array data bank (vTMAB)

  • Launching the health diagnosis kit for obesity and skin disease

  • Participating in the culture and entertainment field

With its sophisticated research in genes, the Company can provide the professional health diagnostic service for its customers. The Company can check the reasons for obesity and other skin diseases like freckles by its genetic analysis, which offers more accurate and specialized diagnosis than other similar services in the current market. Such information can be utilized to guide customers to set up the right health or fitness program. At present, the Company provide genetic test for the mechanism of obesity or skin diseases.

The Company will also explore other business development opportunities that can leverage its sales platform and relationship with affiliated companies. Until such time as the Company can identify attractive marketing opportunities, the Company will loan available cash on a short term unsecured basis to non-affiliated third parties in order to generate interest income.

12


Commencing in the third quarter of 2007, the Company developed a new gene detective tissue array, called New Kits, and began to offer them to its customers.

On July 28, 2007 the Company acquired an 83.33% equity ownership of SD Chaoying from its Chinese partner, which will be primarily engaged in developing and operating culture and entertainment business which is expected to open in 2010. The culture and entertainment business will consist primarily of a spa activities, cosmetic personal care, hotel and casino. Its Chinese partner is a principal shareholder of the Company and Mr. Bai, its chief executive officer and a director is also a principal of its Chinese partner. SD Chaoying began constructing the facility in September 2007. The total useable land and net building area for the project consists of approximately 50,000 and 33,000 square meters, respectively of which 52% will constitute property for business use and 48% for residential use. As of December 31, 2010, SD Chaoying had substantially completed the construction of two residential buildings and had recognized revenue from sales of housing units from these buildings for the year then ended. The project includes four multi-family residential buildings (about 14,188 square meters), and two of them had been completed. Approximately 20.88% of the cultural and entertainment part of the facility opened in January 2011 and the balance remains under construction, but which are expected to be completed in 2011 prior to the commencement of operations by merchant tenants. SD Chaoying intends to focus on Spa activities, cosmetic personal care, hotel and casino gambling, which has been approved by Shandong Administration for Civil Affairs. In January 2011, SD Chaoying entered into a verbal agreement with Dongshan Victoria Spring Hotel (“Victoria”) allowing Victoria to manage and operate the SPA business at the completed section of the cultural and entertainment facility. SD Chaoying agreed not to charge fees from Victoria during the first year of operation as the trial period. As of June 30, 2011, the land use right and construction-in-progress with total book value of $6.74 million (equivalent to RMB 44.00 million) of SD Chaoying were collateralized under the short-term loan of $1,469,791 (equivalent to RMB 9.5 million) from Changle Rural Credit Union.

13


RESULTS OF OPERATIONS

FOR THE THREE MONTHS ENDED JUNE 30, 2011 COMPARED TO THREE MONTHS ENDED JUNE 30, 2010

    Three Months Ended     Three Months Ended              
    June 30, 2011     June 30, 2010   $ Change     % Change  
Revenue                        
       Housing $  -   $  41,835   $  (41,835 )   -100%  
       Commercial rental   -     -     -        
       Tissue array products   123,419     105,107     18,312     17%  
          Total revenue   123,419     146,942     (23,523 )   -16%  
Cost of Sales                        
       Housing   -     48,923     (48,923 )   -100%  
       Commercial rental   17,125     -     17,125     100%  
       Tissue array products   102,176     101,493     683     1%  
           Total cost of sales   119,301     150,416     (31,115 )   -21%  
Gross Profit   4,118     (3,474 )   7,592     -219%  
Operating Expenses:                        
       Professional fees   10,782     8,659     2,123     25%  
       Bad debt expense   23,226     41,943     (18,717 )   -45%  
       Salaries and wages   41,093     45,357     (4,264 )   -9%  
       Depreciation and amortization   36,721     35,376     1,345     4%  
       Other general and administrative expenses   25,407     62,386     (36,979 )   -59%  
       Selling and distribution expenses   3,786     11,291     (7,505 )   -66%  
       Research and development expenses   -     2,754     (2,754 )   -100%  
Total Operating Expenses   141,015     207,766     (66,751 )   -32%  
Loss from Operations   (136,897 )   (211,240 )   74,343     -35%  
Other Income (Expense)                        
       Interest income (expense)   (1,085 )   426     (1,511 )   -355%  
       Other income (expense), net   (14 )   429     (443 )   -103%  
Total Other Income (Expense), Net   (1,099 )   855     (1,954 )   -229%  
Loss before Income Taxes   (137,996 )   (210,386 )   72,389     -34%  
Income Tax Benefit (Expense)   -     -     -        
Net loss   (137,996 )   (210,386 )   72,389     -34%  
Net loss attributable to the noncontrolling interest   (28,160 )   (37,036 )   8,876     -24%  
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES $  (109,836 ) $  (173,350 ) $  63,513     -37%  

Net Sales

Cybrdi generates two categories of revenues, including sales of tissue chip & kits products and residential housing. The net sales decreased $23,523 to $123,419 for the three months ended June 30, 2011 from $146,942 for the three months ended June 30, 2010, a decrease of 16%.

Tissue Chip & Kit Products: The net sales increased $18,312 to $123,419 for the three months ended June 30, 2011 as compared to $105,107 for the three months ended June, 2010, an increase of 17%. The increase in net sales of tissue chip & kit product was primarily because we adjusted the domestic market at the beginning of 2010. Our sole domestic sales representative in China is Xi’an AiLiNa Biotechnology Co., Ltd., and the only overseas sales representative is Biomax. We mainly distribute our products through these two sales representatives.

Housing: No residential units were sold during the second quarter of 2011. SD Chaoying completed the construction of the two six-story multi-family residential buildings with a total of 72 housing units last year, 9 and 37 of which qualified as being recognized as sales revenue aggregating $296,521 and $1,060,632 for the years ended December 31, 2010 and 2009. Since SD Chaoying is required to continue its involvement with the property after the sale, including installations of utility systems, improvements and amenities, and community landscaping, profit from the sale was recognized using the percentage of completion method as required by ASC Topic 360-20, “Property, Plant, and Equipment – Real Estate Sales”.

Gross Margin

Gross margin as a percentage of sales increased to 3.34% for the three months ended June 30, 2011 from (2.36%) for three months ended June 30, 2010. Gross profit for the three months ended in June 30, 2011 increased $7,592 to $4,118 from $(3,474) for the three months ended in June 30, 2010, an increase of 219%. The increase in gross profit and margin was mainly due to stronger overseas sales, a 22% increase, for the three months ended June 30, 2011 as compared to the same period last year. The increase of gross profit was partially offset by weak sales in the residential housing segment, whereas in the commercial property segment, the commencement of the business has not generated revenue but has incurred costs directly associated with the business.

14


Operating Expenses

The Company’s operating expenses decreased $66,751 to $141,015 for the three months ended June 30, 2011 from $207,766 for the three months ended June 30, 2010, a decrease of 32%. This was primarily due to a decrease in Other general and administrative expenses of $36,979 from $62,386 for the three months ended June 30, 2010 to $25,407 for the current quarter and a decrease of $18,717 bad debt from $41,943 for the second quarter prior year to $23,226 for the current quarter

Other Income

Other income decreased by $1,954 to $(1,099) for the three months ended June 30, 2011 as compared to $855 for the three months ended June 30, 2010, a decrease of 229%. The decreased was primarily due to a foreign exchange translation loss from overseas sales for the current quarter.

Income Taxes

The Company did not record U.S. and PRC current income tax for three months ended June 30, 2011, and 2010, since there was no taxable income during these periods.

Net Loss

As a result of the above factors, our net loss before minority interests decreased $72,389, or 34%, from $210,386 for the three months ended June 30, 2010 to $137,996 for the three months ended June 30, 2011.

15


FOR THE SIX MONTHS ENDED JUNE 30, 2011 COMPARED TO SIX MONTHS ENDED JUNE 30, 2010


    Six Months Ended     Six Months Ended              
    June 30, 2011     June 30, 2010   $ Change     % Change  
Revenue                        
       Housing $  -   $  136,450   $  (136,450 )   -100%  
       Commercial rental   -           -     -  
       Tissue array products   237,230     202,937     34,293     17%  
            Total revenue   237,230     339,386     (102,156 )   -30%  
Cost of Sales                        
       Housing   -     133,792     (133,792 )   -100%  
       Commercial rental   31,752           31,752     -  
       Tissue array products   189,324     165,952     23,372     14%  
            Total cost of sales   221,076     299,744     (78,668 )   -26%  
Gross Profit   16,154     39,642     (23,488 )   -59%  
Operating Expenses:                        
       Professional fees   57,108     32,886     24,222     74%  
       Bad debt expense   68,830     41,943     26,887     -  
       Salaries and wages   81,576     389,036     (307,460 )   -79%  
       Depreciation and amortization   72,993     70,733     2,260     3%  
       Other general and administrative expenses   51,762     68,342     (16,580 )   -24%  
       Selling and distribution expenses   10,211     17,966     (7,755 )   -43%  
       Research and development expenses   -     10,157     (10,157 )   -100%  
Total Operating Expenses   342,480     631,063     (288,583 )   -46%  
Loss from Operations   (326,326 )   (591,421 )   265,095     -45%  
Other Income (Expense)                        
       Interest income (expense)   (598 )   1,274     (1,872 )   -147%  
       Other income, net   229     27,518     (27,289 )   -99%  
Total Other Income (Expense), Net   (369 )   28,792     (29,161 )   -101%  
Loss before Income Taxes   (326,695 )   (562,630 )   235,934     -42%  
Income Tax Benefit (Expense)   -     -     -     -  
Net loss   (326,695 )   (562,630 )   235,934     -42%  
Net loss attributable to the noncontrolling interest   (53,169 )   (37,140 )   (16,029 )   43%  
Net loss attributable to CYBRDI, INC. AND SUBSIDIARIES $  (273,526 ) $  (525,490 ) $  251,964     -48%  

Net Sales

Cybrdi generates two categories of revenues, including sales of tissue chip & kits products and residential housing. The net sales decreased $102,156 to $237,230 for the six months ended June 30, 2011 from $339,386 for the six months ended June 30, 2010, a decrease of 30%.

Tissue Chip & Kit Products: The net sales increased $34,293 to $237,230 for the six months ended June 30, 2011 as compared to $202,937 for the six months ended June 30, 2010, an increase of 17%. The increase in net sales of tissue chip & kit product was primarily because we adjusted the domestic market at the beginning of 2010. Our sole domestic sales representative in China is Xi’an AiLiNa Biotechnology Co., Ltd., and the only overseas sales representative is Biomax. We mainly distribute our products through these two sales representatives.

Housing: No residential units were sold during the first half of 2011. SD Chaoying completed the construction of the two six-story multi-family residential buildings with a total of 72 housing units last year, 9 and 37 of which qualified as being recognized as sales revenue aggregating $296,521 and $1,060,632 for the years ended December 31, 2010 and 2009. Since SD Chaoying is required to continue its involvement with the property after the sale, including installations of utility systems, improvements and amenities, and community landscaping, profit from the sale was recognized using the percentage of completion method as required by ASC Topic 360-20, “Property, Plant, and Equipment – Real Estate Sales”.

Gross Margin

Gross margin as a percentage of sales decreased to 6.81% for the six months ended June 30, 2011 from 11.68% for six months ended June 30, 2010. Gross profit for the six months ended June 30, 2011 decreased $23,488 to $16,154 for the six months ended June 30, 2011 from $39,642 for the six months ended June 30, 2010, a decrease of 59%. The decrease in gross profit and margin was mainly due to weak sales in the residential housing segment, whereas in the commercial property segment, the commencement of the business has not generated revenue but has incurred costs directly associated with the business.

16


Operating Expenses

The Company’s operating expenses decreased $288,583 to $342,480 for the six months ended June 30, 2011 from $631,063 for the six months ended June 30, 2010, a decrease of 46%. This was primarily due to a decrease in salaries and wages of $307,460 from $389,036 for the six months ended June 30, 2010 to $81,576 for the current quarter, a decrease of research and development expenses of $10,157 for the six months ended June 30, 2011 to $0 for the current period, and a decrease of $16,580 in other general and administrative expenses from $68,342 for the first half of prior year to $51,762 for the current period, partially offset by an increase of $26,887 in bad debt from $41,943 for the first half of 2010 to $68,830 for the current period and an increase of $24,222 in professional fees from $32,886 for the first half of prior year to $57,108 for the current period.

Other Income

Other income decreased by $29,161 to $(369) for the six months ended June 30, 2011 as compared to $28,792 for the six months ended June 30, 2010, a decrease of 101%. Other income was mainly comprised of $28,168 generated from the sale of non-operating real property of Chao Ying Biotech for the first half of 2010. The net book value of non-operating real property was $38,636 and net proceeds from the sale amounted to $66,804.

Income Taxes

The Company did not record U.S. and PRC current income tax for six months ended June 30, 2011, and 2010, since there was no taxable income during these periods.

Net Loss

As a result of the above factors, our net loss before minority interests decreased $235,934, or 42%, from $562,630 for the six months ended June 30, 2010 to $326,695 for the six months ended June 30, 2011.

LIQUIDITY AND CAPITAL RESOURCES

Operating working capital deficit (total current asset deduct total current liabilities) increased by $357,653 from $(2,315,510) as of December 31, 2010 to $(2,673,163) as of June 30, 2011. The increase was primarily due to a decrease in cash and cash equivalents from $585,020 as of December 31, 2010 to $524,208 as of June 30, 2011, and a decrease in loan to unaffiliated company from $90,877 as of December 31, 2010 to $23,207 as of June 30, 2011, partially offset by an increase in due from related companies from $204,474 as of December 31, 2010 to $247,544 as of June 30, 2011. The $244,649 increase in due to related parties from $2,023,474 as of December 31, 2010 to $2,268,323 as of June 30, 2011 also caused the increase in our working capital deficit.

For investing activities, the Company incurred net cash outflow during the six months ended June 30, 2011. The primary reason was due to the payment of a $38,480 advance for loan to an affiliated company, $87,100 used in the construction in progress of the SD Chaoying project during the three months ended June 30, 2011, and $46,523 used in purchase of operating equipment.

For financing activities, the Company obtained net proceeds of $159,178 from its related parties of the Company for the six months ended June 30, 2011.

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has not demonstrated the ability to generate sufficient cash flows from operations to satisfy its liabilities and sustain operations. The Company had an accumulated deficit of $2,121,407 and $1,847,882 as of June 30, 2011 and December 31, 2010, including net losses of $273,526 and $525,490 for the six months ended June 30, 2011 and 2010, respectively. In addition, current liabilities exceeded current assets by $2,673,163 and $2,315,510 at June 30, 2011 and December 31, 2010, respectively. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

17


The Company finances its operations primarily through short-term bank borrowings and advances from related parties and/or officers/shareholders. In order to complete the construction of SD Chaoying cultural and entertainment center, approximately $2.8 million (equivalent to RMB 19 million) of capital is expected to be needed. The Company, taking into accounts the available banking facilities, internal financial resource, and supports from related companies, believes it has sufficient working capital to meet its present obligation for at least the next twelve months. Management is taking actions to address the company's financial condition and deteriorating liquidity position. The following sets forth management’s plans for dealing with the adverse effects of the conditions:

(a)     Sale of housing inventories: Proceeds to be received from the sale of the remaining housing of the two completed residential buildings are expected to amount to approximately $1.1 million.

(b)    Rental and management fee revenue from the cultural and entertainment center: Annual rental revenue is estimated to be approximately $650,000 per year. Management fee revenue will be charged to commercial tenants at 3% of annual gross revenue.

(c)    Additional advances from related companies and affiliates: Mr. Bai, our Chief Executive Officer, advanced $61,209 to the Company in 2011 to finance operations and the costs to maintain the Company’s public status in the U.S. In addition, Shaanxi Chaoying Beauty & Cosmetics Group, which is also an affiliate, is anticipated to provide up to $764,780 (equivalent to RMB 5 million) of capital to support operational use. During the year 2011, Shaanxi Chaoying Beauty & Cosmetics Group advanced $36,710 to the Company to finance its operations.

The Company may require additional funds and may seek to raise such funds though public and private financings or from other sources. There is no assurance that the above management’s plans will be realized or the additional financing will be available at all or that, if available, such financing will be obtainable on terms favorable to the Company or that any additional financing will not be dilutive. The consolidated financial statements do not include any adjustments that might result from the outcome of those uncertainties.

INFLATION

Inflation has not had a material impact on our business.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this quarterly report on Form 10-Q contain or may contain forward-looking statements that are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous assumptions and other factors that could cause its actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors. Most of these factors are difficult to predict accurately and are generally beyond its control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Readers should carefully review this quarterly report in its entirety, including but not limited to its financial statements and the notes thereto. Except for its ongoing obligations to disclose material information under the Federal securities laws, the Company undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. For any forward-looking statements contained in any document, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

A smaller reporting company is not required to provide the information required by this Item .

18


Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. Under the supervision and with the participation of our management, including our Chief Executive Officer, Yanbiao Bai, and Principal Financial Officer, Yonghong Ren, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective such that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management to allow timely decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting. During the most recent quarter ended June 30, 2011, there has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) ) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

There are no material pending legal proceedings to which we are a party. We received a notice on June 6, 2000 to inform us that we may have a potential liability from waste disposal in the Casmalia Disposal Site at Santa Barbara County, California. We were given a choice of either signing an agreement that would toll the statute of limitations for eighteen (18) months in order to allow us to resolve any liability with the government without incurring costs associated with being named a defendant in a lawsuit, or becoming an immediate defendant in a lawsuit. We signed the tolling agreement. On November 20, 2001, the tolling agreement was extended for an additional 18 months. On May 20, 2003 the tolling agreement was again extended for an additional 18 months and on November 24, 2004 the tolling agreement was again extended for additional 18 months. On June 29, 2004, we received a proposed settlement from the EPA in the amount of $21,131, which had been accrued as other payable. We are waiting for communication from the government concerning payment of the final settlement. As of June 30, 2011 and subsequent to December 31, 2010, the Company had not received further correspondences from the EPA regarding this matter.

Item 1A. Risk Factors

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders

None.

Item 5. Other Information

None

19


Item 6. Exhibits

   
31.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

   
31.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

   
32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

   
32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

XBRL Exhibit
101.INS† XBRL Instance Document.
101.SCH† XBRL Taxonomy Extension Schema Document.
101.CAL† XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF† XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB† XBRL Taxonomy Extension Label Linkbase Document.
101.PRE† XBRL Taxonomy Extension Presentation Linkbase Document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

  CYBRDI, INC.
   
DATE: August 19, 2011 By /s/ Yanbiao Bai
        Yanbiao Bai, Chief Executive Officer and president
     
  By: /s/ Yonghong Ren
         Yonghong Ren, Principal Financial Officer

20